Concepedia

Vassiliki Karantza

VK

77

Publications

16K

Citations

41

H-Index

1993

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Dana-Farber Cancer Institute

Princess Margaret Cancer Centre

Rutgers, The State University of New Jersey

Peter MacCallum Cancer Centre

Vassiliki Karantza is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, breast cancer, and oncology.

ORCID

Top concepts

Publications per year

1993–2025

77

Publications

77

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai et al. · New England Journal of Medicine · 2020 · 2.9K citations · Full text

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés, David W. Cescon, Hope S. Rugo et al. · The Lancet · 2020 · 1.7K citations · Full text

, , +7

Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Andrew Tutt, Judy E. Garber, Bella Kaufman et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda, Laura Q.M. Chow, Elizabeth Claire Dees et al. · Journal of Clinical Oncology · 2016 · 1.4K citations · Full text

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Jessie Yanxiang Guo, Hsin-Yi Chen, Robin Mathew et al. · Genes & Development · 2011 · 1.3K citations · Full text

Rows per page

1–5 of 77